HungaryHungary

Transgenic Crops Could Save Hungarian Farmers 3 Million Euros

06.03.2005

Gödöllö - In January the Hungarian agriculture ministry banned Monsanto's Mon810 transgenic Bt maize from being planted or imported until tests had established whether transgenic crops contaminated other cultures (EuroBiotechNews
1-2/05). According to a recent study of scientists of the Catholic University of Leuven, Belgium, the Hungary Agricultural Economics Research Institute, Budapest, and the Szent István University, Gödöllö, the ban means withholding benefits for Hungarian maize farmers of Euro3 million at 10% adoption. For the study that estimated the potential impact of transgenic maize, sugar beet and oilseed rape for Hungary, the scientists assumed that the crops were introduced in the agricultural season 2003, in which maize, sugar beet and oilseed rape were planted on an acreage of 1,150,000 ha, 53,000 ha and 71,000 ha.
Cornborers and Corn Rootworms Cause Severe Damages
In the Carpathian Basin the European corn borer (Ostrinia nubilalis Hübner) causes substantial losses in the southern part (northern Serbia), while severe damage is caused less frequently in southern parts of the Trans-Tisza region (Hungarian maize belt), on low-lying areas of the Great Hungarian Plain along the Danube, and in parts of Romania. Less severe damage is also incurred in central and western Hungary. The adoption of resistant Bt maize could save Hungarian farmers Euro19/ha on average. This takes into account a seed price premium of Euro6/ha or 10% of the actual seed cost. Assuming an early adoption rate of 10% for 2003, total benefits aggregate to an estimated Euro3 million, of which farmers and the seed industry share 76% and 24% respectively. The appearance of the Western corn rootworm (Diabrotica virgifera virgifera LeConte) in the southern Carpathian Basin is the result of an accidental introduction in Serbia in 1992. Bt maize resistant to this North-American maize pest could also save Hungarian farmers some Euro46/ha (seed price premium of Euro25/ha or 40% of the actual seed cost). Assuming an early adoption rate of 20% in 2003, this translates into a total gain of Euro16 million, with farmers receiving 65% and the seed industry 35%.
Additionally, the introduction of herbicide tolerant maize, sugar beet and oilseed rape could save Hungarian farmers 22, 81 and 20 Euro/ha. The model predicts seed price premiums of 8, 81 and 12 Euro/ha and early adoption rates in 2003 of 40%, 38% and 35%. Herbicide tolerant maize potentially generates Euro14 million, of which 73% is shared by farmers and 27% is extracted by the seed industry. Herbicide tolerant sugar beet involves a further gain of Euro3 million, of which 50% flows to farmers and 50% to the seed industry. Herbicide tolerant oilseed rape could potentially bring a total benefit of Euro0.8 million, of which 61% is for Hungarian farmers and 39% is captured by the seed industry.

HungaryHungary

19.03.2008

Zagreb – Pliva d.d., Barr Pharmaceuticals‘ subsidiary in Croatia, is selling its three operations in Spain – Pliva Pharma Iberia, Laboratorios Edigen and Uso Racional – to Biomedica Foscama Industria Chimico-Farmaceutica. For a...

HungaryHungary

19.03.2008

Budapest – A Hungarian research consortium has been granted a 3-year fund of EUR2m by the Hungarian government to identify new enzyme targets against multi-restistant strains of the tuberculosis agent Mycobacterium tuberculosis...

HungaryHungary

19.02.2008

Debrecen – Israeli generic drugmaker Teva Pharmaceutical Industries is looking to expand its presence in Hungary. The pharma company wants to double capacity at its plant in Debrecen. This will involve a EUR70 million investment...

HungaryHungary

01.01.2008

Szeged – The development of inhibitors directed against matrix metalloproteinases is at the centre of a new funding project sponsored by the Hungarian National Office for Research and Technology (NKTH). The NKTH recently granted...

HungaryHungary

22.11.2007

Budapest/Mumbai – Solvo Biotechnology (Budapest) and Krishgen BioSystems (Mumbai, India) have formed a partnership to distribute and represent Solvo’s membrane transporter assay products and services in India. “Membrane...

HungaryHungary

24.09.2007

Sofia – Icelandic Actavis Group announced double-digit growth in Bulgaria in the first half of 2007. Sales were up 10,65% with more than €23.1 million and 24 new products launched in the first six months of 2007. “Actavis...

HungaryHungary

11.07.2007

Budapest – A new National Alliance for Rare Diseases in Hungary, termed Huferdis – Rare Diseases Hungary (Hungarian Federation of People with Rare and Congenital Diseases), was announced at the beginning of June. “The importance...

HungaryHungary

16.03.2007

Budapest – The EU Environment Council, made up of the European Ministers for the Environment, rejected the proposal in February from the European Commission to lift the Hungarian prohibition to grow genetically modified maize...

HungaryHungary

21.11.2006

Gödöllö – At the end of September, GlaxoSmithKline (GSK) inaugurated a new a100-million vaccine production plant 30 km northeast of the Hungarian capital.According to GSK, the new facility will be one of Europe’s most advanced...

HungaryHungary

21.07.2006

Sofia – On June 1 a law banning the production and sale of a range of genetically modified organisms (GMOs), including wheat, came into effect in Bulgaria. The law represents an about-face for the country, which has experimented...

Displaying results 21 to 30 out of 89

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-hungary/browse/2/article/transgenic-crops-could-save-hungarian-farmers-3-million-euros.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3297.5%
  • GW PHARMACEUTICALS (UK)419.75 GBP642.9%
  • PAION (D)2.77 EUR319.7%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.4%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products